Vincristine sulfate

Vincristine (vincristine sulfate) is a small molecule pharmaceutical. Vincristine sulfate was first approved as Oncovin on 1982-01-01. It is used to treat hodgkin disease, leukemia, neuroblastoma, non-hodgkin lymphoma, and rhabdomyosarcoma amongst others in the USA. The pharmaceutical is active against tubulin beta chain.

Download report

Favorite

Drugs Approved for Childhood Cancers

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
neoplasms	D009369
urogenital diseases	D000091642
hemic and lymphatic diseases	D006425
hereditary congenital and neonatal diseases and abnormalities	D009358
immune system diseases	D007154

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
vincristine sulfate	ANDA	2024-04-24

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

L: Antineoplastic and immunomodulating agents

— L01: Antineoplastic agents

— L01C: Plant alkaloids and other natural products, antineoplastic drugs

— L01CA: Vinca alkaloids and analogues, antineoplastic

— L01CA02: Vincristine

HCPCS

Code	Description
J9370	Vincristine sulfate, 1 mg
J9371	Injection, vincristine sulfate liposome, 1 mg

Clinical

Clinical Trials

1362 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	110	341	146	18	34	591
Precursor cell lymphoblastic leukemia-lymphoma	D054198	—	C91.0	57	135	65	23	21	270
Large b-cell lymphoma diffuse	D016403	—	C83.3	56	143	54	5	9	233
Leukemia	D007938	—	C95	45	118	55	15	18	226
Non-hodgkin lymphoma	D008228	—	C85.9	49	108	58	7	10	207
B-cell lymphoma	D016393	—	—	57	109	37	6	8	184
Lymphoid leukemia	D007945	—	C91	28	72	31	16	9	145
Follicular lymphoma	D008224	—	C82	19	34	33	2	3	80
Sarcoma	D012509	—	—	11	38	16	1	10	72
Burkitt lymphoma	D002051	—	C83.7	21	40	13	2	—	69

Show 28 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neuroblastoma	D009447	EFO_0000621	—	18	24	16	—	4	60
Central nervous system neoplasms	D016543	—	—	9	22	15	—	5	49
Ewing sarcoma	D012512	EFO_0000173	—	8	23	6	—	4	36
Nervous system neoplasms	D009423	—	—	4	17	12	—	4	36
Rhabdomyosarcoma	D012208	—	—	7	19	11	—	2	33
Multiple myeloma	D009101	—	C90.0	5	14	12	—	1	30
Recurrence	D012008	—	—	15	13	4	—	2	30
Precursor t-cell lymphoblastic leukemia-lymphoma	D054218	—	—	9	19	6	—	—	27
Plasma cell neoplasms	D054219	—	—	3	10	10	—	1	24
Brain neoplasms	D001932	EFO_0003833	C71	6	9	6	—	2	22

Show 69 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Plasmablastic lymphoma	D000069293	—	C83.3	7	6	—	—	—	11
Aids-related lymphoma	D016483	EFO_1001365	—	4	6	—	—	—	10
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	3	7	—	—	—	9
Acute disease	D000208	—	—	5	3	—	—	—	8
Syndrome	D013577	—	—	3	6	—	—	—	8
Hematologic neoplasms	D019337	—	—	4	2	—	—	2	7
Blast crisis	D001752	—	—	1	6	—	—	—	7
Adult t-cell leukemia-lymphoma	D015459	—	C91.5	3	3	—	—	—	5
Myeloid leukemia chronic-phase	D015466	—	—	1	3	—	—	—	4
T-cell lymphoma cutaneous	D016410	—	C84.A	2	2	—	—	1	4

Show 74 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pinealoma	D010871	—	—	2	—	—	—	1	3
Neoplasm metastasis	D009362	EFO_0009708	—	2	—	—	—	—	2
Sezary syndrome	D012751	—	C84.1	1	—	—	—	1	2
Mycosis fungoides	D009182	—	C84.0	1	—	—	—	1	2
Myelodysplastic-myeloproliferative diseases	D054437	—	—	2	—	—	—	—	2
Hypersensitivity	D006967	EFO_0003785	T78.40	1	—	—	—	—	1
Deltaretrovirus infections	D006800	EFO_1001303	—	1	—	—	—	—	1
Htlv-i infections	D015490	EFO_0007316	—	1	—	—	—	—	1
Composite lymphoma	D058617	—	—	1	—	—	—	—	1
Rectal neoplasms	D012004	—	—	1	—	—	—	—	1

Show 2 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Vomiting	D014839	—	R11.1	—	—	—	—	3	3
Nausea	D009325	—	R11.0	—	—	—	—	3	3
Constipation	D003248	—	K59.0	—	—	—	—	2	2
Cognitive dysfunction	D060825	—	G31.84	—	—	—	—	1	1
Non-small-cell lung carcinoma	D002289	—	—	—	—	—	—	1	1
Ataxia	D001259	—	R27.0	—	—	—	—	1	1
Ataxia telangiectasia	D001260	Orphanet_100	G11.3	—	—	—	—	1	1
Telangiectasis	D013684	—	—	—	—	—	—	1	1
Cerebellar ataxia	D002524	—	—	—	—	—	—	1	1
Ototoxicity	D000081015	—	—	—	—	—	—	1	1

Show 18 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Vincristine sulfate
INN	vincristine
Description	Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Classification	Small molecule
Drug class	vinca alkaloids
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O